Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000386 | 1.00 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9FPR3 | |
| SCHEMBL2000384 | 1.00 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9FPR3 | |
| SCHEMBL10013663 | 0.88 | NR1H2 (0.48) | EPHX1USP30FPR3FPR2ALDH1A1 | |
| SCHEMBL17560314 | 0.87 | EPHX1 (0.55) | EPHX1USP30HSD11B1CYP2C9FPR3 | |
| SCHEMBL17560313 | 0.87 | EPHX1 (0.55) | EPHX1USP30HSD11B1CYP2C9FPR3 | |
| SCHEMBL2040388 | 0.87 | EPHX1 (0.55) | EPHX1USP30HSD11B1CYP2C9FPR3 | |
| SCHEMBL7456395 | 0.86 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL18632877 | 0.86 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL30505540 | 0.86 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL5118879 | 0.86 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590978-B1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY | FOB SYNTHESIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20150306071-A1 | Carbapenem Antibacterials with Gram-Negative Activity | CHOI, WOO-BAEG, DR. | 2015-10-29 | — | — | US | disclosed |
| US-9149461-B2 | Carbapenem antibacterials with gram-negative activity | FOB SYNTHESIS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130172313-A1 | Carbapenem Antibacterials with Gram-Negative Activity | FOB SYNTHESIS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172313-A1 | Carbapenem Antibacterials with Gram-Negative Activity | MGAM, GSK3B, GSK3A | EPHX1 3387/4885USP30 3027/4885HSD11B1 586/4885 |
| US-20150306071-A1 | Carbapenem Antibacterials with Gram-Negative Activity | MGAM, GSK3B, GSK3A | EPHX1 3387/4885USP30 3027/4885HSD11B1 586/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | EPHX1 3344/4885USP30 4115/4885HSD11B1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.